NBIX Earnings & Financial Statements
Neurocrine Biosciences, Inc.
$135.91
+$0.78(+0.58%)
53
Overall
70
Value
18
Tech
71
Quality
Market Cap
$13.82B
Volume
1.50M
52W Range
$122.14 - $186.12
Target Price
$206.03
NBIX earnings and financial statements: Neurocrine Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NBIX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Cost of revenue | $52.10M | $34.00M | $39.70M | $23.20M | $14.30M |
| Operating income | $619.10M | $570.50M | $250.90M | $249.00M | $102.50M |
| EBITDA | $735.50M | $513.10M | $353.40M | $237.80M | $138.10M |
| Net income | $478.60M | $341.30M | $249.70M | $154.50M | $89.60M |
| EPS (diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B |
| Total liabilities | $1.38B | $1.13B | $1.02B | $660.90M | $698.50M |
| Shareholders’ equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B |
| Cash and equivalents | $713.00M | $233.00M | $251.10M | $262.90M | $340.80M |
| Long-term debt | $415.30M | $455.10M | $258.30M | $93.50M | $440.40M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $782.70M | $595.40M | $389.90M | $339.40M | $256.50M |
| Capital expenditure | -$34.00M | -$38.20M | -$28.30M | -$16.50M | -$23.40M |
| Free cash flow | $748.70M | $557.20M | $361.60M | $322.90M | $233.10M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NBIX | $135.91 | +0.6% | 1.50M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Neurocrine Biosciences, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW